Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation in Children

Area of Science:

• Hematology
• Neuroscience
• Pediatric Oncology

Background:

• Central nervous system complications (CNSCs) are a significant concern after allogeneic hematopoietic stem cell transplantation (allo-HSCT), impacting patient morbidity and mortality.
• Understanding the incidence, types, and risk factors of CNSCs is vital for improving outcomes in pediatric patients.

Purpose of the Study:

• To determine the type, incidence, and survival impact of CNSCs in pediatric patients undergoing allo-HSCT.
• To identify risk factors associated with the development of CNSCs post-allo-HSCT.

Main Methods:

• Retrospective study of 153 pediatric patients who underwent allo-HSCT.
• Analysis of CNSC type, cumulative incidence at 100 days and 3 years, and associated risk factors.
• Evaluation of the impact of CNSCs on overall survival and non-relapse mortality.

Main Results:

• 34 patients (22.2%) developed CNSCs, with a cumulative incidence of 18.30% at 100 days and 22.73% at 3 years.
• Calcineurin inhibitor (CNI)-associated neurotoxicity was the most common CNSC (50.0%).
• Risk factors included time from diagnosis to HSCT ≥4.8 months and grade III-IV acute graft-versus-host disease (aGVHD).

Conclusions:

• CNSCs following allo-HSCT are linked to poorer outcomes, including reduced overall survival and increased non-relapse mortality.
• Patients with severe aGVHD or delayed transplantation require closer monitoring and attention.
• Further research into preventative and therapeutic strategies for CNSCs is warranted.